Phase 4 N=21 Endoscopic Ultrasound (EUS) Guided Treatment With Humira for Crohn's Perianal Fistulas
Crohn Disease · Rectal Fistula
Primary: Number of Participants With Durable Fistula Healing — 7; 8 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=3,032 Perianal Fistula (PAF) Validation and Burden of Illness Study
Inflammatory Bowel Disease · Perianal Fistula · Crohns Disease
Primary: Objective 1: Number of CD Participants Who Have CPAF Using Various Codes in an TOH Database — 120; 120; 127; 127 Participants
Phase 2 N=6 A Study Testing How BI 655130 Works in Patients With Fistulizing Crohn's Disease
Crohn Disease
Primary: The Total Number of Deregulated Genes at Week 4 — 0; 0 Deregulated genes
N/A N=80 Video-assisted Anal Fistula Treatment Versus Seton in the Management of High Peri Anal Fistula
Post Operative Pain · Recurrence
Primary: Number of Participants With Recurrence of Disease or Fistula — 5; 10 Participants
N/A N=26 Prevalence of Inflammatory Bowel Disease in Patients With Perianal Disease
Inflammatory Bowel Disease · Perianal Fistula · Perianal Abscess
Primary: Prevalence of Inflammation as Diagnosed by Capsule Endoscopy — 6 participants
N/A N=15 A Study of the Quality of Life in Adults With Crohn's Disease With Complex Perianal Fistulas
Crohn Disease · Rectal Fistula
Primary: Meta-Scores of the 12-Item Short Form Health Survey (SF-12) Questionnaire's Physical Component Score [PCS-12] — 45.36 score on a scale
Phase 4 N=34 Vedolizumab IV 300 mg in the Treatment of Fistulizing Crohn's Disease
Crohn's Disease
Primary: Percentage of Participants With at Least 50% Reduction From Baseline in the Number of Draining Perianal Fistulae (of Those Draining at Baseline) — 75.0; 75.0 percentage…
Phase 2 N=57 Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn's Disease
Fistulizing Crohn's Disease
Primary: Percentage of Participants Who Achieved Combined Fistula Response at Week 24 — 47.1; 29.2; 25.0 percentage of participants
Phase 3 N=22 Phase 3 Study of Cx601 in Participants With Complex Perianal Fistulising Crohn's Disease
Complex Perianal Fistulas in Adult Participants With Crohn's Disease
Primary: Percentage of Participants With Combined Remission of Perianal Fistulising Crohn's Disease (CD) at Week 24 — 59.1 percentage of participants
Phase 3 N=568 Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Participants With Crohn's Disease (CD)
Crohn's Disease
Primary: Percentage of Participants With Combined Remission at Week 24 — 46.32; 48.76 percentage of participants — p==0.571
N/A N=86 A Randomized Clinical Trial Comparing Surgisis AFP to Advancement Flap for the Repair of Anal Fistulas
Anal Fistula
Primary: Healing Success — 22; 25 participants — p=0.59
Phase 2 N=33 Ciprofloxacin for the Prevention of Postoperative Endoscopic Recurrence in Crohn's Disease
Crohn's Disease
Primary: Safety and Tolerability of Ciprofloxacin — 25; 11; 9; 1 Adverse events
Phase 2 N=8 Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease
Crohn's Disease
Primary: Change in Disease Activity by Harvey Bradshaw Index — -5; -3 score on a scale
N/A N=100 A Prospective, Multi-center, Observational Study of the Use of Permacol™ Collagen Paste to Treat Anorectal Fistulas
Anorectal Fistulas
Primary: Fistula Healing in Patients at 6 Months Following Surgery — 56.7; 43.3 percentage of participants
Phase 2 N=8 FMT in Ulcerative Colitis-Associated Pouchitis
Ulcerative Colitis Associated Pouchitis
Primary: Number of Patients Who Experienced Improvement of Pouchitis Symptoms — 2 Participants
Phase 2 N=10 Pilot Study of Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease
Crohn Disease
Primary: Change in FCP in Group 2 Participants — 1501 mcg/g — p=1.0
Phase 4 N=24 Infliximab for the Prevention of Recurrent Crohn's Disease After Surgery
Crohn's Disease
Primary: Endoscopic Recurrence: the Proportion of Patients in Endoscopic Recurrence at One Year — 1; 11 participants — p=.0005
Phase 3 N=150 Long-term Follow-up Study With Darvadstrocel in the Treatment of Complex Perianal Fistula
Crohn's Disease · Complex Perianal Fistula
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 40; 43 Participants
N/A N=2 Pilot Study Evaluating the Safety and Efficacy of a Patient-Specific Enteroatmospheric Fistula Isolation and Management Device Independent of Negative Pressure Wound Therapy
Fistula · Abdominal Injury · Negative Pressure Wound Therapy
Primary: Change in Inpatient Participant Pain Rating
Phase 2 N=6 Teduglutide for Enterocutaneous Fistula (ECF)
Postoperative Fistula
Primary: Change in Average 3-day Fistula Percent Volume — 76.33; 441.67 Percent change in fistula volume
Phase 2 N=262 Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease
Crohn's Disease
Primary: Percentage of Participants With Crohn's Disease Activity Index (CDAI) 70 Response Rate — 52.7; 60.1; 62.7; 47.7 Percentage of Participants — p=0.3393
Phase 2 N=21 Effect of Sclerotherapy on Fistulas and Sinus Tracts in Hidradenitis Suppurativa
Hidradenitis Suppurativa
Primary: HS Physician Local Improvement Assessment - PAIN — 7; 7; 2 Participants
Phase 4 N=55 Triple Combination Therapy in High Risk Crohn's Disease (CD)
Crohn Disease
Primary: Percentage of Participants Achieving Endoscopic Remission at Week 26 — 34.5 percentage of participants
Phase 2 N=54 Dietary Treatment of Crohn's Disease
Crohn's Disease · Inflammatory Bowel Disease
Primary: Number of Participants With Flare Up of Crohn's Disease Through Month 12 — 6; 4; 0 participants
Phase 3 N=396 CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Crohn's Disease (LIBERTY-CD)
Crohn's Disease
Primary: Percentage of Patients Achieving Clinical Remission (Based on CDAI) at Week 54 — 144; 36 Participants — p=<0.0001
Phase 4 N=30 Intestinal Inflammation in Ankylosing Spondylitis and the Effects of Adalimumab on Mucosal Healing
Spondyloarthritis · Enterocolitis
Primary: Change Lewis Score Index — -225 units on a scale
Phase 1 N=23 Fecal Microbiota Transplantation in Pediatric Patients
Inflammatory Bowel Diseases (IBD) · Crohn's Disease (CD) · Ulcerative Colitis (UC)
Primary: Number of Occurrences of Adverse Events at 6 Months According to Adverse Event Term — 11; 5; 5; 3 Events
Phase 2 N=75 PillCam® Platform With the PillCam Crohn's Disease Capsule
Crohn's Disease
Primary: Per-subject Diagnostic Yield of the PillCam Platform With the CD Capsule Within the Terminal Ileum and Colon as Compared to the Ileocolonoscopy Diagnostic Yield Within…
Phase 3 N=945 Study of Adalimumab Treatment for Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease
Crohn's Disease
Primary: Number of Participants in Clinical Remission at Treatment Week 20. Clinical Remission Defined as Harvey Bradshaw Index (HBI) Score Less Than 5. — 492 Participants
Phase 3 N=244 Efficacy and Safety of Two Treatment Algorithms in Adults With Moderate to Severe Crohn's Disease
Crohn's Disease
Primary: Percentage of Participants With Mucosal Healing and No Deep Ulcerations — 30.3; 45.9 percentage of participants — p=0.010